De-Risking Receipt // LOCKED
â–ˆ
LATIFY De-Risking Map
PhasePhase III
DrugCeralasertib (ATRi, AZD6738) + Durvalumab (PD-L1)
EndpointOS primary endpoint: FAILED (HR 0.90, p=0.287)
3/3 PASS+0.3658
De-Risking Receipt // Sealed
LATIFY De-Risking Map
Ceralasertib (ATRi) + Durvalumab (PD-L1) // AZ Phase III NSCLC failure
RegistryNCT05450692
SponsorAstraZeneca
PhasePhase III
IndicationIO-refractory NSCLC
Mechanistic Stratification
Patient Vector Signature
Root Cause Verdict
Enrollment Gate Recommendation
Analysis withheldPasscode required